Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HER2-positive breast cancer that has spread to distant organs (stage IV) and you have not received any prior treatment for invasive breast cancer.
- You are 18 years or older.
- You are in good physical shape (ECOG performance status 0 or 1).
- Your heart pumps at least 50% of blood out with each beat (LVEF ≥ 50%).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- If you have brain metastases, they must have been treated and stable.
- You are not pregnant and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This study tests whether combining surgery or strong focused radiation with standard treatment can help people whose HER2-positive breast cancer has spread to a few spots (5 or fewer) in the body, but not the brain. It's for patients whose cancer is stable after at least 3 months of first-line therapy.
This trial tests a sequence of different treatments for breast cancer that has spread, based on how the cancer evolves. The goal is to find a personalized treatment plan that may work better over time.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.